Literature DB >> 32860619

Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study.

Qiongyang Yu1, Xiurui Ma2,3, Yunan Wang1, Haozhe Shi1, Jian An3, Yuhui Wang1, Zhen Dong2,4,5, Yijing Lu2,6, Junbo Ge2,4,5,6, George Liu7,8, Xunde Xian9, Aijun Sun10,11,12,13.   

Abstract

PURPOSE: Statins are inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, which is involved in cholesterol synthesis. The major side effects of statins include muscle- and liver-related toxicity. Muscle toxicity is highly associated with polymorphisms in cytochrome P450 proteins (CYPs), as predicted by pharmacogenomics. However, the mechanisms of hepatotoxicity are not well understood. Due to differences in cholesterol metabolism, statins are well tolerated in mice. In contrast, hamsters exhibit metabolic traits similar to humans and are suitable for studying the hepatotoxicity of statins.
METHODS: We investigated the effect of rosuvastatin (RSV) on liver damage in wild-type (WT) hamsters fed a high-cholesterol diet (HCD) and LDLR knockout (LDLR-/-) hamsters that developed spontaneous hypercholesterolemia. Two cohorts of clinical subjects (clinical registry number: 2017001) taking atorvastatin (ATV) were recruited for direct (assessment of cholesterol intake individually, n = 44) and indirect (celebratory meals/holiday season, n = 1993) examination of dietary cholesterol intake and liver damage, as indicated by elevation of alanine aminotransferase (ALT).
RESULTS: RSV at a dose of 10 mg/kg caused fatal liver damage only in HCD-fed WT hamsters, while LDLR-/- hamsters with the same cholesterol levels were resistant to this toxic effect. In the human studies, we observed that the incidence of hepatic toxicity in patients receiving long-term ATV treatment was higher in patients with greater dietary cholesterol intake and in patients who consumed more food during Chinese holidays.
CONCLUSION: Our results propose, for the first time, that dietary cholesterol significantly contributes to statin-related hepatotoxicity, providing valuable insight into the clinical use of statins.

Entities:  

Keywords:  Hamster; Hepatotoxicity; Hypercholesterolemia; Statins

Mesh:

Substances:

Year:  2020        PMID: 32860619     DOI: 10.1007/s10557-020-07060-3

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  25 in total

1.  Structural mechanism for statin inhibition of HMG-CoA reductase.

Authors:  E S Istvan; J Deisenhofer
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

2.  Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.

Authors:  Einar Björnsson; Elin I Jacobsen; Evangelos Kalaitzakis
Journal:  J Hepatol       Date:  2011-09-01       Impact factor: 25.083

Review 3.  3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.

Authors:  Maria Tzefos; Jacqueline L Olin
Journal:  J Clin Lipidol       Date:  2011-06-28       Impact factor: 4.766

Review 4.  Regulation of HMG-CoA reductase in mammals and yeast.

Authors:  John S Burg; Peter J Espenshade
Journal:  Prog Lipid Res       Date:  2011-07-23       Impact factor: 16.195

5.  Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen.

Authors:  M M Farag; M B Mohamed; E A Youssef
Journal:  Hum Exp Toxicol       Date:  2014-11-25       Impact factor: 2.903

6.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

Review 7.  Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors.

Authors:  Jonathan A Tobert
Journal:  Nat Rev Drug Discov       Date:  2003-07       Impact factor: 84.694

8.  SLCO1B1 variants and statin-induced myopathy--a genomewide study.

Authors:  E Link; S Parish; J Armitage; L Bowman; S Heath; F Matsuda; I Gut; M Lathrop; R Collins
Journal:  N Engl J Med       Date:  2008-07-23       Impact factor: 91.245

9.  Spontaneously reported hepatic adverse drug events in Korea: multicenter study.

Authors:  Hee Kwon; Suk-Hyang Lee; Seong-Eun Kim; Jae-Hyun Lee; Yung-Koo Jee; Hye-Ryun Kang; Byung-Joo Park; Jung-Won Park; Chein-Soo Hong
Journal:  J Korean Med Sci       Date:  2012-02-23       Impact factor: 2.153

10.  Statin Safety in Chinese: A Population-Based Study of Older Adults.

Authors:  Daniel Q Li; Richard B Kim; Eric McArthur; Jamie L Fleet; Robert A Hegele; Baiju R Shah; Matthew A Weir; Amber O Molnar; Stephanie Dixon; Jack V Tu; Sonia Anand; Amit X Garg
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

View more
  1 in total

1.  The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice.

Authors:  Zhi-Chao Dong; Ming-Ming Wu; Yun-Long Zhang; Qiu-Shi Wang; Chen Liang; Xiao Yan; Lei-Xin Zou; Chen Chen; Xiao Han; Bo Zhang; Zhi-Ren Zhang
Journal:  Acta Pharmacol Sin       Date:  2020-12-10       Impact factor: 7.169

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.